0001213900-21-068127.txt : 20211230 0001213900-21-068127.hdr.sgml : 20211230 20211230161516 ACCESSION NUMBER: 0001213900-21-068127 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211230 DATE AS OF CHANGE: 20211230 EFFECTIVENESS DATE: 20211230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-427466 FILM NUMBER: 211533008 BUSINESS ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 D 1 primary_doc.xml X0708 D LIVE 0001536196 Can-Fite BioPharma Ltd. 10 BAREKET STREET, KIRYAT MATALON PETACH TIKVA L3 ISRAEL 4951778 972 39241114 ISRAEL None None Corporation true Ilan Cohn 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Pnina Fishman 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Executive Officer Director Yossi Bornstein 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Motti Farbstein 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Executive Officer Guy Regev 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Abraham Sartani 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Yaacov Goldman 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Pharmaceuticals Decline to Disclose 06b false 2021-12-20 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 10000000 10000000 0 The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with the immediate exercise of certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 ADSs. false 1 700000 0 H.C. Wainwright is also entitled to non-accountable expense reimbursement of $75,000 and warrants to purchase an aggregate of 350,000 ADSs exercisable at $2.00 per ADS for five years. 0 Issuer expects to use proceeds from the offering for working capital which includes payment of salaries to the named executive officers. false Can-Fite BioPharma Ltd. /s/ Motti Farbstein Motti Farbstein Chief Operating and Financial Officer 2021-12-30